516 related articles for article (PubMed ID: 27881650)
1. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
[TBL] [Abstract][Full Text] [Related]
3. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
4. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.
Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A
Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180
[TBL] [Abstract][Full Text] [Related]
5. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
[TBL] [Abstract][Full Text] [Related]
6. Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F.
Albin JS; Anderson JS; Johnson JR; Harjes E; Matsuo H; Krogan NJ; Harris RS
J Mol Biol; 2013 Apr; 425(7):1172-82. PubMed ID: 23318957
[TBL] [Abstract][Full Text] [Related]
7. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
[TBL] [Abstract][Full Text] [Related]
8. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
Dang Y; Wang X; York IA; Zheng YH
J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
[TBL] [Abstract][Full Text] [Related]
9. Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.
Dang Y; Davis RW; York IA; Zheng YH
J Virol; 2010 Jun; 84(11):5741-50. PubMed ID: 20335268
[TBL] [Abstract][Full Text] [Related]
10. APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.
Li J; Chen Y; Li M; Carpenter MA; McDougle RM; Luengas EM; Macdonald PJ; Harris RS; Mueller JD
J Mol Biol; 2014 Mar; 426(6):1296-307. PubMed ID: 24361275
[TBL] [Abstract][Full Text] [Related]
11. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS
J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
Liu B; Sarkis PT; Luo K; Yu Y; Yu XF
J Virol; 2005 Aug; 79(15):9579-87. PubMed ID: 16014920
[TBL] [Abstract][Full Text] [Related]
13. Stably expressed APOBEC3F has negligible antiviral activity.
Miyagi E; Brown CR; Opi S; Khan M; Goila-Gaur R; Kao S; Walker RC; Hirsch V; Strebel K
J Virol; 2010 Nov; 84(21):11067-75. PubMed ID: 20702622
[TBL] [Abstract][Full Text] [Related]
14. Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1.
Apolonia L; Schulz R; Curk T; Rocha P; Swanson CM; Schaller T; Ule J; Malim MH
PLoS Pathog; 2015 Jan; 11(1):e1004609. PubMed ID: 25590131
[TBL] [Abstract][Full Text] [Related]
15. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.
Smith JL; Bu W; Burdick RC; Pathak VK
Trends Pharmacol Sci; 2009 Dec; 30(12):638-46. PubMed ID: 19837465
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.
Cadima-Couto I; Saraiva N; Santos AC; Goncalves J
J Neuroimmune Pharmacol; 2011 Jun; 6(2):296-307. PubMed ID: 21279453
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
Holmes RK; Koning FA; Bishop KN; Malim MH
J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
[TBL] [Abstract][Full Text] [Related]
18. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
Albin JS; Harris RS
Expert Rev Mol Med; 2010 Jan; 12():e4. PubMed ID: 20096141
[TBL] [Abstract][Full Text] [Related]
19. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
Mariani R; Chen D; Schröfelbauer B; Navarro F; König R; Bollman B; Münk C; Nymark-McMahon H; Landau NR
Cell; 2003 Jul; 114(1):21-31. PubMed ID: 12859895
[TBL] [Abstract][Full Text] [Related]
20. APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.
Mbisa JL; Bu W; Pathak VK
J Virol; 2010 May; 84(10):5250-9. PubMed ID: 20219927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
